Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cc 10004
2. Cc-10004
3. Cc10004
4. Otezla
1. 608141-41-9
2. Otezla
3. Cc-10004
4. Cc 10004
5. Apremilast (cc-10004)
6. Cc10004
7. (s)-n-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide
8. Chebi:78540
9. Up7qbp99pn
10. Chembl514800
11. N-{2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1h-isoindol-4-yl}acetamide
12. N-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide
13. (s)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
14. N-{2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1h-isoindol-4-yl}acetamide
15. (+)-n-(2-((1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxo- 2,3-dihydro-1h-isoindol-4-yl)acetamide
16. Apremilast [usan]
17. Apremilast [usan:inn]
18. Unii-up7qbp99pn
19. Apremilastum
20. Mfcd18782607
21. Hsdb 8221
22. Apremilast- Bio-x
23. Otezla (tn)
24. Apremilast [mi]
25. Apremilast [inn]
26. Apremilast [jan]
27. Apremilast (jan/usan)
28. Apremilast [vandf]
29. Apremilast [who-dd]
30. Schembl302992
31. Amy371
32. Gtpl7372
33. Apremilast [orange Book]
34. Dtxsid30976289
35. Ex-a336
36. Cas:608141-41-9;apremilast
37. 608141-44-2
38. Bcp03783
39. Bcp25283
40. Bdbm50248919
41. S8034
42. Zinc30691736
43. Akos016339660
44. Bcp9000311
45. Ccg-269336
46. Cs-0671
47. Db05676
48. Fk-0727
49. Ac-27650
50. Ba164215
51. Hy-12085
52. Bcp0726000109
53. Sw219856-1
54. D08860
55. Q2858961
56. (s)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione(apremilast)
57. (s)-n-{2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1h-isoindol-4-yl}-acetamide
58. 4-[[5 Pound Not7-dihydroxy-2 Pound Not2-dimethyl-8-(2-methylpropanoyl)chromen-6-yl]methy L]-3 Pound Not5-dihydroxy-6 Pound Not6-dimethyl-2-(2-methylpropanoyl)cyclohexa-2 Pound Not4-dien- 1-one
59. A9l
60. Acetamide, N-(2-((1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)- 2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl)-
61. Acetamide, N-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]-
62. N-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]acetamide
Molecular Weight | 460.5 g/mol |
---|---|
Molecular Formula | C22H24N2O7S |
XLogP3 | 1.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 8 |
Exact Mass | 460.13042228 g/mol |
Monoisotopic Mass | 460.13042228 g/mol |
Topological Polar Surface Area | 128 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 825 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Inflammatory Agents, Non-Steroidal; Phosphodiesterase Inhibitors
National Library of Medicine's Medical Subject Headings. Apremilast. Online file (MeSH, 2014). Available from, as of December 18, 2014: https://www.nlm.nih.gov/mesh/2014/mesh_browser/MBrowser.html
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis. /Included in US product label/
NIH; DailyMed. Current Medication Information for Otezla (Apremilast) Tablet, Film Coated (Revised: October 2014). Available from, as of December 31, 2014: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66
Otezla is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. /Included in US product label/
NIH; DailyMed. Current Medication Information for Otezla (Apremilast) Tablet, Film Coated (Revised: October 2014). Available from, as of December 31, 2014: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66
EXPL THER /The purpose of this study is/ to evaluate the efficacy and safety of an oral phosphodiesterase 4 inhibitor, apremilast, in treatment of ankylosing spondylitis (AS) by monitoring symptoms and signs in a pilot study including exploratory investigation of effects of PDE4 inhibition on blood biomarkers of bone biology. In this double-blind, placebo-controlled, single-centre, Phase II study, patients with symptomatic AS with active disease on MRI were randomized to apremilast 30 mg BID or placebo over 12 weeks. Bath Indices were monitored serially. Patients were followed for 4 weeks after stopping medication. Bone biomarkers were assessed at baseline and day 85. 38 subjects were randomised and 36 subjects completed the study. Although the primary end-point (change in BASDAI at week 12) was not met, apremilast was associated with numerically greater improvement from baseline for all clinical assessments compared with placebo with mean change in BASDAI (-1.59 + or - 1.48 vs -0.77 + or - 1.47), BASFI (-1.74 + or - 1.91 vs -0.28 + or - 1.61) and BASMI (-0.51 + or - 1.02 vs -0.21 + or - 0.67); however, differences did not achieve statistical significance. The clinical indices returned to baseline values by 4 weeks after cessation of apremilast. Six apremilast patients (35.3%) vs 3 placebo (15.8%) achieved ASAS20 responses (p=0.25). There were statistically significant decreases in serum RANKL and RANKL:osteoprotegrin ratio and plasma sclerostin but no significant changes in serum DKK-1, bone alkaline phosphatase, TRAP5b, MMP3, osteoprotegrin, or osteocalcin. Although a small pilot study, these results suggest that apremilast may be effective and well tolerated in AS and modulates biomarkers of bone biology. These data support further research of apremilast in axial inflammation.
PMID:22984171 Pathan E et al; Ann Rheum Dis 72 (9): 1475-80 (2013)
EXPL THER Discoid lupus erythematosus (DLE) is a chronic inflammatory disorder mediated by Th1 cells. Apremilast is a novel oral PDE4 enzyme inhibitor capable of blocking leukocyte production of IL-12, IL-23, TNF-a, INF- with subsequent suppression of Th1 and Th17-mediated immune responses, and proven clinical efficacy for psoriasis as well as rheumatoid and psoriatic arthritis. Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) showed a significant (P<0.05) decrease after 85 days of treatment with apremilast 20 mg twice daily in 8 patients with active discoid lupus. The adverse events related to the drug were mild and transient. This is the first open label study to use apremilast as a treatment modality for discoid lupus. Our observations indicate that apremilast may constitute a safe and effective therapeutic option for DLE.
PMID:23134988 De Souza A et al; J Drugs Dermatol 11 (10): 1224-6 (2012)
Treatment with Otezla is associated with an increase in adverse reactions of depression. Before using Otezla in patients with a history of depression and/or suicidal thoughts or behavior prescribers should carefully weigh the risks and benefits of treatment with Otezla in such patients. Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and if such changes occur to contact their healthcare provider. Prescribers should carefully evaluate the risks and benefits of continuing treatment with Otezla if such events occur.
NIH; DailyMed. Current Medication Information for Otezla (Apremilast) Tablet, Film Coated (Revised: October 2014). Available from, as of February 25, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66
The safety and effectiveness of Otezla in pediatric patients less than 18 years of age have not been established.
NIH; DailyMed. Current Medication Information for Otezla (Apremilast) Tablet, Film Coated (Revised: October 2014). Available from, as of February 25, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66
It is not known whether Otezla or its metabolites are present in human milk; however apremilast was detected in milk of lactating mice. Because many drugs are present in human milk, caution should be exercised when Otezla is administered to a nursing woman.
NIH; DailyMed. Current Medication Information for Otezla (Apremilast) Tablet, Film Coated (Revised: October 2014). Available from, as of February 25, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66
FDA Pregnancy Risk Category: C /RISK CANNOT BE RULED OUT. Adequate, well controlled human studies are lacking, and animal studies have shown risk to the fetus or are lacking as well. There is a chance of fetal harm if the drug is given during pregnancy; but the potential benefits may outweigh the potential risk./
NIH; DailyMed. Current Medication Information for Otezla (Apremilast) Tablet, Film Coated (Revised: October 2014). Available from, as of February 25, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66
For more Drug Warnings (Complete) data for Apremilast (11 total), please visit the HSDB record page.
Apremilast is indicated for the treatment of adults with active psoriatic arthritis and adults with oral ulcers associated with Behcet's Disease. In addition, apremilast is indicated for the treatment of plaque psoriasis, of any severity, in adult patients who are candidates for phototherapy or systemic therapy.
* Psoriatic arthritis :
Otezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
* Psoriasis:
Otezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).
Treatment of Behcet disease
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis , ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis )
Treatment of psoriasis
Apremilast reduces but does not completely inhibit various inflammatory cytokines such as IL-1, IL-6, IL-8, IL-10 MCP-1, MIP-1, MMP-3, and TNF-, relieving the symptoms of psoriasis and Behcet's disease, which are caused by an increase in these inflammatory mediators. This drug has also been proven to be effective in relieving the pain associated with oral ulcers in Behcet's disease. Apremilast may cause unwanted weight loss and worsen depression, leading to suicidal thoughts or actions. It is advisable to monitor for symptoms of depression and seek medical attention if they occur, especially in patients with pre-existing depression. The need for apremilast should be carefully assessed along with the risk of worsening depression and suicide. If weight loss occurs, the degree of weight loss should be evaluated, and consideration should be made for the possible discontinuation of apremilast.
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Phosphodiesterase 4 Inhibitors
Compounds that specifically inhibit PHOSPHODIESTERASE 4. (See all compounds classified as Phosphodiesterase 4 Inhibitors.)
L04AA32
L - Antineoplastic and immunomodulating agents
L04 - Immunosuppressants
L04A - Immunosuppressants
L04AA - Selective immunosuppressants
L04AA32 - Apremilast
Absorption
An oral dose of apremilast is well-absorbed and the absolute bioavailability is approximately 73%. Tmax is approximately 2.5 hours and Cmax has been reported to be approximately 584 ng/mL in one pharmacokinetic study. Food intake does not appear to affect apremilast absorption.
Route of Elimination
Only 3% and 7% of an apremilast dose are detected in the urine and feces as unchanged drug, respectively, indicating extensive metabolism and high absorption.
Volume of Distribution
The average apparent volume of distribution (Vd) is about 87 L, suggesting that apremilast is distributed in the extravascular compartment.
Clearance
In healthy patients, the plasma clearance of apremilast is about 10 L/hour.
Human plasma protein binding of apremilast is approximately 68%. Mean apparent volume of distribution (Vd) is 87 L.
NIH; DailyMed. Current Medication Information for Otezla (Apremilast) Tablet, Film Coated (Revised: October 2014). Available from, as of February 25, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66
The lacteal excretion of apremilast was evaluated following oral administration of apremilast to lactating CD-1 mice. In this study, female mice approximately 13 days postpartum received a single oral dose of apremilast at 10 mg/kg, administered by oral gavage in a volume of 10 mL/kg. Milk and blood samples from 5 animals per time point were obtained at 1, 6, and 24 hr postdose and apremilast concentrations determined in plasma and milk using LC-MS/MS analysis. The mean apremilast plasma concentrations at 1 and 6 hr post-dose were 984 and 138 ng/mL, while concentrations in milk were 1441 and 186 ng/mL, respectively. The resulting mean milk-to-plasma ratios ranged from 1.46 to 1.62, indicating transfer of apremilast into milk in mice. Plasma and milk concentrations were below the detection limit of 3 ng/mL in the 24-hr samples.
European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Otezla (Apremilast) p.35 (November 20, 2014). Available from, as of February 26, 2015: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003746/WC500182629.pdf
In monkeys, pregnant animals were administered daily oral doses of apremilast beginning on gestation day 20 through gestation day 50, and a single oral dose on gestation day 100 at dosages of 20, 50, 200, and 1000 mg/kg/day (n = 16/group at the beginning of the study). Maternal and fetal blood was collected at 5 hr postdose on gestation Day 100. In all dosage groups, the fetal-to-maternal plasma concentration ratios were between 0.3 and 0.4, indicating apremilast crossed the placenta in monkeys.
European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Otezla (Apremilast) p.34-5 (November 20, 2014). Available from, as of February 26, 2015: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003746/WC500182629.pdf
As part of fertility and developmental toxicity study in female CD-1 mice and an embryo-fetal development study in cynomolgus monkeys, the transport of apremilast across the placenta was assessed. In mice, following daily oral administration of apremilast beginning 15 days prior to cohabitation and continuing through Day 15 of presumed gestation at doses of 10, 20, 40, and 80 mg/kg/day, blood was collected from pregnant mice (n = 3/time point) at 0.5, 2, 4, 8, and 24 hr postdose on gestation Day 15. Blood was collected from fetuses) at the time of sacrifice in the 24 hr postdose mice. Maternal plasma apremilast concentrations increased in a less than dose proportional manner. The fetal plasma concentrations at 24 hr were highly variable, with six of the ten litters evaluated being below the limit of quantification (1 ng/mL). In fetal plasma from four of the ten litters evaluated, apremilast was quantified, with concentrations ranging from 14.5 to 2813 ng/mL. The mean fetal-to-maternal plasma concentration ratios ranged from 0.3 to 1.07, indicating apremilast crossed the placenta in mice.
European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Otezla (Apremilast) p.34 (November 20, 2014). Available from, as of February 26, 2015: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003746/WC500182629.pdf
For more Absorption, Distribution and Excretion (Complete) data for Apremilast (13 total), please visit the HSDB record page.
Apremilast is heavily metabolized by various pathways, which include oxidation, hydrolysis, in addition to conjugation. About 23 metabolites are produced from its metabolism. The CYP3A4 primarily mediates the oxidative metabolism of this drug, with smaller contributions from CYP1A2 and CYP2A6 enzymes. The main metabolite of apremilast, M12, is an inactive glucuronide conjugate form of the O-demethylated drug. Some other major metabolites, M14 and M16, are significantly less active in the inhibition of PDE4 and inflammatory mediators than their parent drug, apremilast. After an oral dose, unchanged apremilast (45%) and the inactive metabolite, O-desmethyl apremilast glucuronide (39%) are found in the plasma. Minor metabolites M7 and M17 are active, but are only present in about 2% or less of apremilast concentrations, and likely not significant contributors to the actions of apremilast.
The plasma clearance of apremilast is about 10 L/hr in healthy subjects, with a terminal elimination half-life of approximately 6-9 hours. Following oral administration of radio-labeled apremilast, about 58% and 39% of the radioactivity is recovered in urine and feces, respectively, with about 3% and 7% of the radioactive dose recovered as apremilast in urine and feces, respectively.
NIH; DailyMed. Current Medication Information for Otezla (Apremilast) Tablet, Film Coated (Revised: October 2014). Available from, as of February 25, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66
Following oral administration in humans, apremilast is a major circulating component (45%) followed by inactive metabolite M12 (39%), a glucuronide conjugate of O-demethylated apremilast. It is extensively metabolized in humans with up to 23 metabolites identified in plasma, urine and feces. Apremilast is metabolized by both cytochrome (CYP) oxidative metabolism with subsequent glucuronidation and non-CYP mediated hydrolysis. In vitro, CYP metabolism of apremilast is primarily mediated by CYP3A4, with minor contributions from CYP1A2 and CYP2A6.
NIH; DailyMed. Current Medication Information for Otezla (Apremilast) Tablet, Film Coated (Revised: October 2014). Available from, as of February 25, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66
In /an/ oral study, concentrations of both total radioactivity (e.g., parent compound plus any metabolites) and of parent compound in plasma were greater in females than in males. In males, the total radioactivity AUC values were 25 to 96 times greater than those for parent compound, whereas in females the difference was only 2- to 3-fold, suggesting that metabolism was more extensive in male than in female rats. In the same study following six daily doses, accumulation was indicated by Cmax and AUC values in females, but not in males.
European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Otezla (Apremilast) p.32 (November 20, 2014). Available from, as of February 26, 2015: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003746/WC500182629.pdf
In a bile-duct cannulated male mouse study following a single 10 mg/kg oral dose of (14)C-apremilast, 54% and 16% of the radioactive dose was excreted via the biliary and urinary routes, suggesting that at least 70% of the radioactive dose was absorbed in mice, indicating apremilast is subject to moderate first pass metabolism. Toxicokinetic evaluation in mice suggests exposure increases dose-proportionally and less than dose-proportionally at doses over 100 mg/kg/day. The studies do not indicate sex-related differences or inversion of apremilast to its R enantiomer in mice.
European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Otezla (Apremilast) p.32 (November 20, 2014). Available from, as of February 26, 2015: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003746/WC500182629.pdf
For more Metabolism/Metabolites (Complete) data for Apremilast (6 total), please visit the HSDB record page.
The average elimination half-life of this drug ranges from 6-9 hours.
terminal elimination half-life of approximately 6-9 hours
NIH; DailyMed. Current Medication Information for Otezla (Apremilast) Tablet, Film Coated (Revised: October 2014). Available from, as of February 25, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66
The full mechanism of action of this drug is not fully established, however, it is known that apremilast is an inhibitor of phosphodiesterase 4 (PDE4), which mediates the activity of cyclic adenosine monophosphate (cAMP), a second messenger. The inhibition of PDE4 by apremilast leads to increased intracellular cAMP levels. An increase in cAMP results in the suppression of inflammation by decreasing the expression of TNF-, IL-17, IL-23, and other inflammatory mediators. The above inflammatory mediators have been implicated in various psoriatic conditions as well as Behcet's disease, leading to their undesirable inflammatory symptoms such as mouth ulcers, skin lesions, and arthritis. Apremilast administration leads to a cascade which eventually decreases the levels of the above mediators, relieving inflammatory symptoms.
Apremilast is an orally administered phosphodiesterase-4 inhibitor, currently in phase 2 clinical studies of psoriasis and other chronic inflammatory diseases. The inhibitory effects of apremilast on pro-inflammatory responses of human primary peripheral blood mononuclear cells (PBMC), polymorphonuclear cells, natural killer (NK) cells and epidermal keratinocytes were explored in vitro, and in a preclinical model of psoriasis. Apremilast was tested in vitro against endotoxin- and superantigen-stimulated PBMC, bacterial peptide and zymosan-stimulated polymorphonuclear cells, immunonoglobulin and cytokine-stimulated NK cells, and ultraviolet B light-activated keratinocytes. Apremilast was orally administered to beige-severe combined immunodeficient mice, xenotransplanted with normal human skin and triggered with human psoriatic NK cells. Epidermal skin thickness, proliferation index and inflammation markers were analysed. Apremilast inhibited PBMC production of the chemokines CXCL9 and CXCL10, cytokines interferon-gamma and tumour necrosis factor (TNF)-alpha, and interleukins (IL)-2, IL-12 and IL-23. Production of TNF-alpha by NK cells and keratinocytes was also inhibited. In vivo, apremilast significantly reduced epidermal thickness and proliferation, decreased the general histopathological appearance of psoriasiform features and reduced expression of TNF-alpha, human leukocyte antigen-DR and intercellular adhesion molecule-1 in the lesioned skin. Apremilast displayed a broad pattern of anti-inflammatory activity in a variety of cell types and decreased the incidence and severity of a psoriasiform response in vivo. Inhibition of TNF-alpha, IL-12 and IL-23 production, as well as NK and keratinocyte responses by this phosphodiesterase-4 inhibitor suggests a novel approach to the treatment of psoriasis.
PMID:20050849 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829210 Schafer PH et al; Br J Pharmacol 159 (4): 842-55 (2010)
Psoriasis and psoriatic arthritis are common clinical conditions that negatively impact health-related quality of life and are linked to serious medical comorbidities. Disease mechanisms involve local and systemic chronic inflammatory processes. Available biologic therapies specifically target single inflammatory mediators, such as tumor necrosis factor-a (TNF-a), in the context of a larger inflammatory signaling cascade. To interrupt this pathological cascade earlier in the response or further upstream, and return pro-inflammatory and anti-inflammatory signaling to a homeostatic balance, the use of a phosphodiesterase4 (PDE4) inhibitor has been explored. PDE4 is the major enzyme class responsible for the hydrolysis of cyclic adenosine monophosphate (cAMP), an intracellular second messenger that controls a network of pro-inflammatory and anti-inflammatory mediators. With PDE4 inhibition, and the resulting increases in cAMP levels in immune and non-immune cell types, expression of a network of pro-inflammatory and anti-inflammatory mediators can be modulated. Apremilast is an orally available targeted PDE4 inhibitor that modulates a wide array of inflammatory mediators involved in psoriasis and psoriatic arthritis, including decreases in the expression of inducible nitric oxide synthase, TNF-a, and interleukin (IL)-23 and increases IL-10. In phase II studies of subjects with psoriasis and psoriatic arthritis, apremilast reversed features of the inflammatory pathophysiology in skin and joints and significantly reduces clinical symptoms. The use of an oral targeted PDE4 inhibitor for chronic inflammatory diseases, like psoriasis and psoriatic arthritis, represents a novel treatment approach that does not target any single mediator, but rather focuses on restoring a balance of pro-inflammatory and anti-inflammatory signals.
PMID:22257911 Schafer P; Biochem Pharmacol 83 (12): 1583-90 (2012)
Apremilast, a small-molecule inhibitor of phosphodiesterase 4 (PDE4), works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. Phosphodiesterase 4 inhibition elevates intracellular cAMP levels, thereby reducing the inflammatory response by modulating the expression of tumor necrosis factor-alpha (TNF-a), interleukin-23 (IL-23), IL-17 and IL-10.
Health Canada; Product Monograph for Otezla (Apremilast), Drug Identification Number (DIN): 02434318 p.13 (Date of Preparation: November 12, 2014). Available from, as of February 25, 2015: https://webprod5.hc-sc.gc.ca/dpd-bdpp/start-debuter.do?lang=eng
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-04-07
Pay. Date : 2016-12-20
DMF Number : 31141
Submission : 2016-11-09
Status : Active
Type : II
Available Reg Filing : ASMF, CA |
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-01-05
Pay. Date : 2016-11-15
DMF Number : 30732
Submission : 2016-09-30
Status : Active
Type : II
Date of Issue : 2022-07-28
Valid Till : 2025-12-30
Written Confirmation Number : WC-0390
Address of the Firm :
NDC Package Code : 55111-988
Start Marketing Date : 2017-12-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Sangjin Corporation
Registration Date : 2022-06-22
Registration Number : No. 583-31-ND
Manufacturer Name : Dr. Reddy's Laboratories Limited
Manufacturer Address : CTO-SEZ Process Unit-01, Sector No.'s 28 to 34, 36 to 37, 40, 50 to 53 & 03, Survey No.'s 57 to 58, 60, 72 to 73, 76 to 77 & 80, Devunipalavalasa Village, Srikakulam District, Andhra Pradesh-532 409, India
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32953
Submission : 2018-11-06
Status : Active
Type : II
Date of Issue : 2022-06-07
Valid Till : 2025-06-16
Written Confirmation Number : WC-0037
Address of the Firm :
NDC Package Code : 58032-2030
Start Marketing Date : 2018-11-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2020-12-17
Registration Number : Su434-25-ND
Manufacturer Name : Neuland Laboratories Limited (Unit-II)
Manufacturer Address : Plot Nos. 92, 93, 94, 257, 258, 259 IDA, Pashamylaram, Isnapur Village, Patancheru Mandal, Sangareddy District – 502 319, Telangana State India
Available Reg Filing : ASMF |
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-10-02
Pay. Date : 2017-08-29
DMF Number : 31356
Submission : 2017-06-02
Status : Active
Type : II
Date of Issue : 2022-07-28
Valid Till : 2025-12-30
Written Confirmation Number : WC-0390
Address of the Firm :
NDC Package Code : 55111-993
Start Marketing Date : 2017-06-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-07-28
Valid Till : 2025-12-30
Written Confirmation Number : WC-0390
Address of the Firm : Devunipalavalasa Village, Ranasthalam Mandal, Srikakulam District -532409, Andhr...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-07-28
Valid Till : 2025-12-30
Written Confirmation Number : WC-0390
Address of the Firm : Devunipalavalasa Village, Ranasthalam Mandal, Srikakulam District -532409, Andhr...
Date of Issue : 2022-06-07
Valid Till : 2025-06-16
Written Confirmation Number : WC-0037
Address of the Firm : Unit II Plot No. 92-94, 257-259, IDA, Pashamylaram, Isnapur Village, Patancheru ...
Date of Issue : 2022-06-17
Valid Till : 2025-02-07
Written Confirmation Number : WC-0082
Address of the Firm : Karakhadi Plot No. 842-843, At - Karakhdi, Tal. - Padra, Dist - Vadodara 391 450...
Date of Issue : 2023-11-28
Valid Till : 2026-11-28
Written Confirmation Number : WC-0310
Address of the Firm : Plot No. Z-103/l, Dahej SEZ, Phase II, Dahej, Dist-Bharuch, Gujarat, India
Date of Issue : 2022-06-09
Valid Till : 2025-12-08
Written Confirmation Number : WC-0077
Address of the Firm : Block No. 422, ECP Canal Road Village - Luna, Tal - Padra, Dist - Vadodara GUjar...
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0023
Address of the Firm : Survey no. 52,53,58,59,61 to 78,127&128, Pydibhimanvaram Village &Sy.No. 1,2,4t0...
Date of Issue : 2022-06-20
Valid Till : 2025-08-08
Written Confirmation Number : WC-0113
Address of the Firm : Old Madras Road, Virgo Nagar Post, Bengaluru - 560 049
Date of Issue : 2022-07-06
Valid Till : 2025-06-16
Written Confirmation Number : WC-0049
Address of the Firm : Block-21, Dabhasa, Tal- Padra, Dist- Vadodara-391440 Gujarat, India
Date of Issue : 2022-07-27
Valid Till : 2025-07-21
Written Confirmation Number : WC-0087
Address of the Firm : Plot No.1 to 5, 31 to 35 & 48 to 51, 26 & Kl201, Village Lakhmapur, Taluka Dindo...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.
Lead Product(s): Apremilast
Therapeutic Area: Dermatology Brand Name: Otezla-Generic
Study Phase: Approved FDFProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 12, 2022
Lead Product(s) : Apremilast
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.
Product Name : Otezla-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
January 12, 2022
Details:
Otezla® (apremilast) is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP), indicated for the treatment of plaque psoriasis in adults.
Lead Product(s): Apremilast
Therapeutic Area: Dermatology Brand Name: Otezla
Study Phase: Approved FDFProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 19, 2023
Lead Product(s) : Apremilast
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amgen Wins Patent Appeal on Otezla® (apremilast)
Details : Otezla® (apremilast) is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP), indicated for the treatment of plaque psoriasis in adults.
Product Name : Otezla
Product Type : HPAPI
Upfront Cash : Inapplicable
April 19, 2023
Details:
Presentations will cover a range of clinical data for Otezla® (apremilast), including positive, 16-week results from the Phase 3 SPROUT study in children ages 6-17 with moderate to severe plaque psoriasis.
Lead Product(s): Apremilast
Therapeutic Area: Dermatology Brand Name: Otezla
Study Phase: Phase IIIProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 30, 2022
Lead Product(s) : Apremilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Presentations will cover a range of clinical data for Otezla® (apremilast), including positive, 16-week results from the Phase 3 SPROUT study in children ages 6-17 with moderate to severe plaque psoriasis.
Product Name : Otezla
Product Type : HPAPI
Upfront Cash : Inapplicable
August 30, 2022
Details:
16-week data demonstrated clinically meaningful and statistically significant improvement in genital psoriasis, with twice many patients achieving primary endpoint of clear (0) or almost clear (1) sPGA-G scale receiving Otezla (apremilast) when compared with placebo.
Lead Product(s): Apremilast
Therapeutic Area: Dermatology Brand Name: Otezla
Study Phase: Phase IIIProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 09, 2022
Lead Product(s) : Apremilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amgen Announces Positive New Data At EADV 2022 For Otezla® (Apremilast)
Details : 16-week data demonstrated clinically meaningful and statistically significant improvement in genital psoriasis, with twice many patients achieving primary endpoint of clear (0) or almost clear (1) sPGA-G scale receiving Otezla (apremilast) when compared ...
Product Name : Otezla
Product Type : HPAPI
Upfront Cash : Inapplicable
August 09, 2022
Details:
New data further reinforces clinical benefit of Otezla (apremilast) is an oral small-molecule inhibitor of phosphodiesterase 4 in mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis.
Lead Product(s): Apremilast
Therapeutic Area: Dermatology Brand Name: Otezla
Study Phase: Approved FDFProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 25, 2022
Lead Product(s) : Apremilast
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amgen Announces New Otezla (Apremilast) Data at AAD Congress 2022
Details : New data further reinforces clinical benefit of Otezla (apremilast) is an oral small-molecule inhibitor of phosphodiesterase 4 in mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis.
Product Name : Otezla
Product Type : HPAPI
Upfront Cash : Inapplicable
March 25, 2022
Details:
The adverse events observed in the trial were consistent with the known safety profile of Otezla. The most commonly reported (≥5%) treatment-emergent adverse events with Otezla treatment were diarrhea, headache, nausea and nasopharyngitis.
Lead Product(s): Apremilast
Therapeutic Area: Dermatology Brand Name: Otezla
Study Phase: Approved FDFProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2021
Lead Product(s) : Apremilast
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Otezla® (Apremilast) for The Treatment of Adult Patients with Plaque Psoriasis, Rega...
Details : The adverse events observed in the trial were consistent with the known safety profile of Otezla. The most commonly reported (≥5%) treatment-emergent adverse events with Otezla treatment were diarrhea, headache, nausea and nasopharyngitis.
Product Name : Otezla
Product Type : HPAPI
Upfront Cash : Inapplicable
December 20, 2021
Details:
Zydus Pharmaceuticals (USA) Inc. has received final approval from the US Food and Drug Administration (FDA) to market apremilast tablets in the strengths of 10 mg, 20 mg, 30 mg tablets are indicated for treatment of adult patients with plaque psoriasis.
Lead Product(s): Apremilast
Therapeutic Area: Dermatology Brand Name: Apremilast-Generic
Study Phase: Approved FDFProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 24, 2021
Lead Product(s) : Apremilast
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Cadila gets US FDA Marketing Approval for Apremilast Tablets
Details : Zydus Pharmaceuticals (USA) Inc. has received final approval from the US Food and Drug Administration (FDA) to market apremilast tablets in the strengths of 10 mg, 20 mg, 30 mg tablets are indicated for treatment of adult patients with plaque psoriasis.
Product Name : Apremilast-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
September 24, 2021
Details:
Otezla® (apremilast) has potential to be first and only approved oral therapy for the mild-to-moderate patient population. Acceptance based on data from Phase 3 ADVANCE Study, demonstrating clinically meaningful improvements through week 32.
Lead Product(s): Apremilast
Therapeutic Area: Dermatology Brand Name: Otezla
Study Phase: Approved FDFProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 05, 2021
Lead Product(s) : Apremilast
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (Apremilast) For Adults With Mi...
Details : Otezla® (apremilast) has potential to be first and only approved oral therapy for the mild-to-moderate patient population. Acceptance based on data from Phase 3 ADVANCE Study, demonstrating clinically meaningful improvements through week 32.
Product Name : Otezla
Product Type : HPAPI
Upfront Cash : Inapplicable
May 05, 2021
Details:
The company has received tentative approval from US Food and Drug Administration for its abbreviated new drug application (ANDA) Apremilast tablets in the strengths of 10 mg, 20 mg, and 30 mg, Shilpa Medicare said in a regulatory filing.
Lead Product(s): Apremilast
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 03, 2021
Lead Product(s) : Apremilast
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shilpa Medicare Gets Tentative American Health Regulator Nod for Apremilast Tablets
Details : The company has received tentative approval from US Food and Drug Administration for its abbreviated new drug application (ANDA) Apremilast tablets in the strengths of 10 mg, 20 mg, and 30 mg, Shilpa Medicare said in a regulatory filing.
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
May 03, 2021
Details:
The sNDA is based on data from the Phase 3 ADVANCE trial that demonstrated oral Otezla 30 mg twice daily achieved a statistically significant improvement in the primary endpoint of the static Physician's Global Assessment (sPGA) response at week 16 compared to placebo.
Lead Product(s): Apremilast
Therapeutic Area: Dermatology Brand Name: Otezla
Study Phase: Phase IIIProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 22, 2021
Lead Product(s) : Apremilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-...
Details : The sNDA is based on data from the Phase 3 ADVANCE trial that demonstrated oral Otezla 30 mg twice daily achieved a statistically significant improvement in the primary endpoint of the static Physician's Global Assessment (sPGA) response at week 16 compa...
Product Name : Otezla
Product Type : HPAPI
Upfront Cash : Inapplicable
February 22, 2021
CAS Number : 7533-40-6
End Use API : Apremilast
About The Company : PMC Isochem is a CDMO company acquired by PMC International in 2017. It manufactures cGMP intermediates, active pharmaceutical ingredients and functional excipi...
(S)-1-(3-Ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl...
CAS Number : 608141-42-0
End Use API : Apremilast
About The Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutica...
CAS Number : 6296-53-3
End Use API : Apremilast
About The Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutica...
CAS Number : 603-11-2
End Use API : Apremilast
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
3-ETHOXY-4-METHOXY BENZALDEHYDE
CAS Number : 1131-52-8
End Use API : Apremilast
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
3-ETHOXY-4-METHOXY BENZONITRILE
CAS Number : 60758-86-3
End Use API : Apremilast
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
3-ACETAMIDO PHTHALIC ANHYDRIDE
CAS Number : 6296-53-3
End Use API : Apremilast
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)eth...
CAS Number : 253168-94-4
End Use API : Apremilast
About The Company : Aventus Labs is a forward-thinking pharmaceutical company committed to developing and delivering high-quality, effective healthcare solutions. With a focus on r...
S-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)e...
CAS Number : 608141-42-0
End Use API : Apremilast
About The Company : Aventus Labs is a forward-thinking pharmaceutical company committed to developing and delivering high-quality, effective healthcare solutions. With a focus on r...
S-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)e...
CAS Number : 608141-43-1
End Use API : Apremilast
About The Company : Aventus Labs is a forward-thinking pharmaceutical company committed to developing and delivering high-quality, effective healthcare solutions. With a focus on r...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code :
Brand Name : APREMILAST
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 2023-07-14
Application Number : 211756
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code :
Brand Name : APREMILAST
Dosage Form : TABLET;ORAL
Dosage Strength : 20MG
Approval Date : 2023-07-14
Application Number : 211756
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code :
Brand Name : APREMILAST
Dosage Form : TABLET;ORAL
Dosage Strength : 30MG
Approval Date : 2023-07-14
Application Number : 211756
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
RLD : No
TE Code : AB
Brand Name : APREMILAST
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 2024-02-07
Application Number : 211734
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
RLD : No
TE Code : AB
Brand Name : APREMILAST
Dosage Form : TABLET;ORAL
Dosage Strength : 20MG
Approval Date : 2024-02-07
Application Number : 211734
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
RLD : No
TE Code : AB
Brand Name : APREMILAST
Dosage Form : TABLET;ORAL
Dosage Strength : 30MG
Approval Date : 2024-02-07
Application Number : 211734
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : APREMILAST
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 2021-09-21
Application Number : 211761
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code : AB
Brand Name : OTEZLA
Dosage Form : TABLET;ORAL
Dosage Strength : 20MG
Approval Date : 2014-03-21
Application Number : 205437
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD : No
TE Code : AB
Brand Name : APREMILAST
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 2024-12-16
Application Number : 211887
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : APREMILAST
Dosage Form : TABLET;ORAL
Dosage Strength : 30MG
Approval Date : 2024-12-16
Application Number : 211887
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Regulatory Info : EU Dossier Readiness-Q3 2020
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q3 2020
Registration Country : Germany
Regulatory Info : EU Dossier Readiness-Q3 2020
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q3 2020
Registration Country : Germany
Regulatory Info : EU Dossier Readiness-Q3 2020
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q3 2020
Registration Country : Germany
Regulatory Info :
Registration Country : Switzerland
Brand Name : Otezla starter pack
Dosage Form : Film-Coated Tablets
Dosage Strength : 10mg and 20mg and 30mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Otezla
Dosage Form : FILMDRAGERAD TABLETT
Dosage Strength : 30 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Otezla
Dosage Form : FILMDRAGERAD TABLETT
Dosage Strength : 10 MG + 20 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Otezla
Dosage Form :
Dosage Strength :
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Otezla
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 30 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Canada
Brand Name : OTEZLA
Dosage Form : TABLET
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number : 2434318
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : OTEZLA
Dosage Form : TABLET
Dosage Strength : 30MG
Packaging : 28/56/60
Approval Date :
Application Number : 2434334
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : AURO-APREMILAST
Dosage Form : TABLET
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number : 2524104
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : AURO-APREMILAST
Dosage Form : TABLET
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number : 2524120
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : GLN-APREMILAST
Dosage Form : TABLET
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number : 2518910
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : JAMP APREMILAST
Dosage Form : TABLET
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number : 2528959
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : JAMP APREMILAST
Dosage Form : TABLET
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number : 2528967
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : MINT-APREMILAST
Dosage Form : TABLET
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number : 2525747
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : SANDOZ APREMILAST
Dosage Form : TABLET
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number : 2529084
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : SANDOZ APREMILAST
Dosage Form : TABLET
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number : 2529092
Regulatory Info :
Registration Country : Canada
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
Brand Name :
Dosage Form : Oral Solid Dosage Form
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Packaging :
Regulatory Info : Lead Market Dossiers- Filed
Dosage : Oral Solid Dosage Form
Dosage Strength : 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
Brand Name :
Dosage Form : Oral Solid Dosage Form
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Packaging :
Regulatory Info : Lead Market Dossiers- Filed
Dosage : Oral Solid Dosage Form
Dosage Strength : 20MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
Brand Name :
Dosage Form : Oral Solid Dosage Form
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Packaging :
Regulatory Info : Lead Market Dossiers- Filed
Dosage : Oral Solid Dosage Form
Dosage Strength : 30MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info : EU Dossier Readiness-Q3 2020
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q3 2020
Registration Country : Germany
Packaging :
Regulatory Info : EU Dossier Readiness-Q3 2020
Dosage : Film Coated Tablet
Dosage Strength : 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Germany
Regulatory Info : EU Dossier Readiness-Q3 2020
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q3 2020
Registration Country : Germany
Packaging :
Regulatory Info : EU Dossier Readiness-Q3 2020
Dosage : Film Coated Tablet
Dosage Strength : 20MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Germany
Regulatory Info : EU Dossier Readiness-Q3 2020
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q3 2020
Registration Country : Germany
Packaging :
Regulatory Info : EU Dossier Readiness-Q3 2020
Dosage : Film Coated Tablet
Dosage Strength : 30MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Germany
Regulatory Info :
Registration Country : Spain
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Packaging :
Regulatory Info :
Dosage : Film Coated Tablet
Dosage Strength : 20MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Spain
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Film Coated Tablet
Dosage Strength : 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : Portugal
Brand Name :
Dosage Form : Coated Tablet
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Portugal
Packaging :
Regulatory Info :
Dosage : Coated Tablet
Dosage Strength : 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Portugal
Regulatory Info :
Registration Country : Portugal
Brand Name :
Dosage Form : Coated Tablet
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Portugal
Packaging :
Regulatory Info :
Dosage : Coated Tablet
Dosage Strength : 30MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Portugal
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : Microlose (Lactose Monohydrate & Microcrystalline Cellulose) is used as a diluent in oral dosage forms such as tablets.
Pharmacopoeia Ref : DMF, EXCiPAT, KOSHER, HALAL, W...
Technical Specs : Lactose Monohydrate – 40%, Microcrystalline cellulose – 60%
Ingredient(s) : Lactose Monohydrate
Dosage Form : Capsule
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : ProBlend (SMCC) is a co-processed excipient consists of microcrystalline cellulose & colloidal silicon dioxide, used as a diluent & binder in OSDs.
Pharmacopoeia Ref : USP-NF, DMF, EXCiPAT, KOSHER, ...
Technical Specs : NA
Ingredient(s) : Silicified Microcrystalline Cellulose
Dosage Form : Capsule
Grade : Oral
Application : Disintegrants & Superdisintegrants
Excipient Details : Sallyso (Croscarmellose Sodium) is a cross-linked polymer of carboxymethylcellulose sodium, used as a superdisintegrant in tablets and capsules.
Pharmacopoeia Ref : USP-NF, BP, IP, EP, DMF, EXCiP...
Technical Specs : Sallyso 0.5 to 3.0%
Ingredient(s) : Croscarmellose Sodium
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : Starlose P40 (Starch & Lactose Monohydrate) is used as a diluent in oral dosage forms such as tablets.
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Lactose Monohydrate
Application : Parenteral
Excipient Details : Lactose monohydrate is used as a diluent in inhalation and lyophilized preparations.
Dosage Form : Tablet
Grade : Oral
Brand Name : Carboxymethylcellulose So...
Application : Fillers, Diluents & Binders
Excipient Details : Tablet binders and disintegrants
Dosage Form : Tablet
Grade : Oral
Brand Name : Croscarmellose Sodium
Application : Disintegrants & Superdisintegrants
Excipient Details : Tablet and capsule disintegrant.
Pharmacopoeia Ref : USP/BP/EP/CP
Technical Specs : Not Available
Ingredient(s) : Croscarmellose Sodium
Dosage Form : Tablet
Grade : Not Available
Brand Name : Magnesium Stearate
Application : Lubricants & Glidants
Excipient Details : Lubricants, Anti-adhesive, Glidant
Dosage Form : Tablet
Grade : Oral
Brand Name : Microcrystalline Cellulos...
Application : Fillers, Diluents & Binders
Excipient Details : Tablet and capsule diluent, Tablet disintegrant.
Pharmacopoeia Ref : USP/BP/EP/CP
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Pharmacopoeia Ref : Conforms to USP-NF, Ph.Eur., J...
Technical Specs : Density- Tapped density- 440 g/l, Bulk density- 280 g/l; Particle size- D10- 25 ?m, D50- 60 ?m, D90-...
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Direct Compression
Pharmacopoeia Ref : Conforms to USP-NF, Ph.Eur., J...
Technical Specs : Density- Tapped density- 440 g/l, Bulk density- 310 g/l; Particle size- D10- 40 ?m, D50- 90 ?m, D90...
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Capsule
Grade : Oral
Application : Fillers, Diluents & Binders
Pharmacopoeia Ref : Conforms to USP-NF, Ph.Eur., J...
Technical Specs : Density- Tapped density- 857 g/l, Bulk density- 589 g/l; Particle size- D10- 5 ?m, D50- 40 ?m, D90-...
Ingredient(s) : Lactose Monohydrate
Dosage Form : Orodispersible Tablet
Grade : Oral
Application : Disintegrants & Superdisintegrants
Pharmacopoeia Ref : Conforms to USP-NF, Ph.Eur., J...
Technical Specs : Not Available
Ingredient(s) : Croscarmellose Sodium
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Pharmacopoeia Ref : Conforms to USP-NF, Ph.Eur., J...
Technical Specs : Density- Tapped density- 716 g/l, Bulk density- 599 g/l; Particle size- D10-50 ?m, D50- 120 ?m, D90-...
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : F-Melt Type C is a pharmaceutical excipient used in oral dosage forms like orally disintegrating tablets, sachets, dispersible tablets, chewable tablets and sublingual tablets.
Pharmacopoeia Ref : Conforms to Japanese Pharmaceu...
Technical Specs : Not Available
Ingredient(s) : Crospovidone
Dosage Form : Orodispersible Tablet
Grade : Oral
Application : Disintegrants & Superdisintegrants
Excipient Details : F-Melt Type M is used in various dosage forms like orally disintegrating tablets (ODTs), sachets, dispersible tablets, chewable tablets and sublingual formulations.
Pharmacopoeia Ref : Conforms to Japanese Pharmaceu...
Technical Specs : Not Available
Ingredient(s) : Crospovidone
Dosage Form : Capsule
Grade : Oral
Application : Coating Systems & Additives
Excipient Details : Ready mix Film coating system for moisture sensitive APIs
Pharmacopoeia Ref : USP, EP, JP; Having US-DMF
Technical Specs : Moisture barrier film coating system
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Controlled & Modified Release
Excipient Details : Espheres EM can be used as an inert base for modified release formulations promoting uniformity of release profile.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Not Available
Brand Name : Disintequik™ MCC 25
Application : Co-Processed Excipients
Excipient Details : Direct Tabletting Operations Where Fast Disintegration Is Required
Dosage Form : Tablet
Grade : Not Available
Brand Name : Foremost Fast Flo® 316
Application : Fillers, Diluents & Binders
Excipient Details : Foremost Fast Flo® 316 is a pharmaceutical excipient used in direct compression.
Pharmacopoeia Ref : USP/NF, EP, and JP
Technical Specs : Not Available
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Not Available
Brand Name : Foremost™ Lactose 313
Application : Fillers, Diluents & Binders
Excipient Details : Wet Granulation & Capsule Filling
Pharmacopoeia Ref : USP/NF, EP, and JP
Technical Specs : Not Available
Ingredient(s) : Lactose Monohydrate
Dosage Form : Capsule
Grade : Not Available
Brand Name : Foremost™ Lactose 315
Application : Fillers, Diluents & Binders
Excipient Details : Foremost™ Lactose 315 is a pharmaceutical excipient used in direct compression.
Pharmacopoeia Ref : USP/NF, EP, and JP
Technical Specs : Not Available
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Not Available
Brand Name : Foremost® Lactose 310
Application : Fillers, Diluents & Binders
Excipient Details : Wet Granulation & Capsule Filling
Pharmacopoeia Ref : USP/NF, EP, and JP
Technical Specs : Not Available
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Not Available
Brand Name : Foremost® Lactose 312
Application : Fillers, Diluents & Binders
Excipient Details : Wet Granulation & Capsule Filling
Pharmacopoeia Ref : USP/NF, EP, and JP
Technical Specs : Not Available
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Not Available
Application : Co-Processed Excipients
Excipient Details : Direct Compression
Pharmacopoeia Ref : NF/EP/JP
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Not Available
Application : Co-Processed Excipients
Excipient Details : Standard Direct Tabletting Or Roller Compaction
Dosage Form : Tablet
Grade : Not Available
Application : Co-Processed Excipients
Excipient Details : Direct Compression
Pharmacopoeia Ref : NF/EP/JP
Technical Specs : Not Available
Ingredient(s) : Spray Dried Monohydrate Lactose
Dosage Form : Inhaler
Grade : Not Available
Brand Name : Monohydrate Inhalation 12...
Application : Fillers, Diluents & Binders
Excipient Details : Dry Powder Inhalation
Dosage Form : Tablet
Grade : Oral
Brand Name : Croscarmellose Sodium
Application : Disintegrants & Superdisintegrants
Excipient Details : Cross Carmellose Sodium is fast disintegrating agent or a super-disintegrant used in pharmaceutical tablet formulations.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Croscarmellose Sodium
Dosage Form : Tablet
Grade : Oral
Brand Name : Microcrystalline Cellulos...
Application : Fillers, Diluents & Binders
Excipient Details : Microcrystalline Cellulose is most commonly used filler and binder in drug formulations, together with Lactose.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Brand Name : Microlex® LCM 120.s
Application : Granulation
Pharmacopoeia Ref : Monograph- USP/NF, JP/JPE
Technical Specs : Sieved; Also Available as Microlex® LCM 180.s, Microlex® LCM 220.s
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Oral
Brand Name : Microlex® LCM 80.m
Application : Granulation
Pharmacopoeia Ref : Monograph- USP/NF, JP/JPE
Technical Specs : Milled; Also Available as Microlex® LCM 180.m, Microlex® LCM 200.m
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Oral
Brand Name : Microlex® MCC 101
Application : Granulation
Excipient Details : Tablets made from these granules are typically easily disintegrated using conventional super disintegrates even when hard tablets are compressed.
Pharmacopoeia Ref : Monograph- USP/NF, JP/JPE
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Brand Name : Microlex® MCC 102
Application : Direct Compression
Pharmacopoeia Ref : Monograph- USP/NF, JP/JPE
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Lubricants & Glidants
Excipient Details : Most popular excipient for the production of tablets and capsules. Offering an efficient and low dosage in capsules.
Pharmacopoeia Ref : Monograph- Ph.Eur, USP/NF
Technical Specs : Specific Surface Area-6-10 m2/g; Particle Size-7-11 µm
Ingredient(s) : Magnesium Stearate
Dosage Form : Tablet
Grade : Oral
Application : Lubricants & Glidants
Excipient Details : Higher specific surface area and a smaller median particle size. This product is preferred for more critical and very fine herbal formulations.
Pharmacopoeia Ref : Monograph- Ph.Eur, USP/NF
Technical Specs : Specific Surface Area-8-12 m2/g; Particle Size-5-9 µm
Ingredient(s) : Magnesium Stearate
Dosage Form : Tablet
Grade : Oral
Application : Lubricants & Glidants
Pharmacopoeia Ref : Monograph- Ph.Eur, USP/NF
Technical Specs : Specific Surface Area-6-8 m2/g; Particle Size-7-11 µm
Ingredient(s) : Magnesium Stearate
Dosage Form : Tablet
Grade : Oral
Application : Lubricants & Glidants
Pharmacopoeia Ref : Monograph- Ph.Eur, USP/NF
Technical Specs : Not Available
Ingredient(s) : Magnesium Stearate
Dosage Form : Tablet
Grade : Oral
Application : Lubricants & Glidants
Excipient Details : Meets Kosher and Halal preparations in Jewish and Arab cultures. Qualified in high specification standards requested by European formulators.
Pharmacopoeia Ref : Monograph- Ph.Eur, USP/NF
Technical Specs : Not Available
Ingredient(s) : Magnesium Stearate
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : TABCELL serves as an excellent excipient for solid dosage forms, providing numerous advantages for tablet formulations.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Lubricants & Glidants
Excipient Details : TABLUBE is one of the oldest and most widely used lubricants for tablet, capsules and other solid dosage forms.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Magnesium Stearate
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Dosage Form : Tablet
Grade : Oral
Dosage Form : Injectable / Parenteral
Grade : Oral, Parenteral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Capsule
Grade : Oral
Application : Fillers, Diluents & Binders
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Lubricants & Glidants
Dosage Form : Tablet
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : Helps to manufacture Oral Dosage and Nutraceutical forms by acting as a filler-binder while serving as a fibre source for your customers.
Pharmacopoeia Ref : EP/USP/JP
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Not Available
Application : Disintegrants & Superdisintegrants
Excipient Details : It is a superdisintegrant that provides an efficient disintegration at low level of use
Dosage Form : Cream / Lotion / Ointment
Grade : Not Available
Application : Thickeners and Stabilizers
Excipient Details : A co-processed product used as a secondary stabilizer and suspension agent in semi-solides formulas.
Pharmacopoeia Ref : EP/USP/JP
Technical Specs : Not Available
Ingredient(s) : Colloidal Microcrystalline Cellulose
Dosage Form : Cream / Lotion / Ointment
Grade : Not Available
Application : Thickeners and Stabilizers
Excipient Details : A co-processed product used as a secondary stabilizer and suspension agent in semi-solides formulas.
Pharmacopoeia Ref : EP/USP/JP
Technical Specs : Not Available
Ingredient(s) : Colloidal Microcrystalline Cellulose
Dosage Form : Cream / Lotion / Ointment
Grade : Not Available
Application : Thickeners and Stabilizers
Excipient Details : A co-processed product used as a secondary stabilizer and suspension agent in semi-solides formulas.
Pharmacopoeia Ref : EP/USP/JP
Technical Specs : Not Available
Ingredient(s) : Colloidal Microcrystalline Cellulose
Dosage Form : Cream / Lotion / Ointment
Grade : Not Available
Brand Name : TABULOSE® SC 591F
Application : Thickeners and Stabilizers
Excipient Details : A co-processed product used as a secondary stabilizer and suspension agent in semi-solides formulas.
Pharmacopoeia Ref : EP/USP/JP
Technical Specs : Not Available
Ingredient(s) : Colloidal Microcrystalline Cellulose
Dosage Form : Cream / Lotion / Ointment
Grade : Not Available
Application : Thickeners and Stabilizers
Excipient Details : A co-processed product used as a secondary stabilizer and suspension agent in semi-solides formulas.
Pharmacopoeia Ref : EP/USP/JP
Technical Specs : Not Available
Ingredient(s) : Colloidal Microcrystalline Cellulose
Dosage Form : Cream / Lotion / Ointment
Grade : Not Available
Application : Thickeners and Stabilizers
Excipient Details : A co-processed product used as a secondary stabilizer and suspension agent in semi-solides formulas.
Pharmacopoeia Ref : EP/USP/JP
Technical Specs : Not Available
Ingredient(s) : Colloidal Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : It is used as a filler in formulation.
Pharmacopoeia Ref : Not Available
Technical Specs : Also Available as Comprecel M102, M102CG, M103, M105, M124, M113, M200, M224, M301, M302
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Capsule
Grade : Not Available
Application : Disintegrants & Superdisintegrants
Excipient Details : It is used as a disintegrating agent.
Pharmacopoeia Ref : Not Available
Technical Specs : Also Available as Disolcel® GF
Ingredient(s) : Croscarmellose Sodium
Dosage Form : Tablet
Grade : Oral
Application : Lubricants & Glidants
Excipient Details : It is used as a lubricant.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Magnesium Stearate
Dosage Form : Tablet
Grade : Oral
Application : Granulation
Excipient Details : AceCel is suitable for majority of the directly compressible actives, combines good flow and high compressibility.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Granulation
Excipient Details : HiCel acts as a strong dry binder. It facilitates low tablet friability & promotes rapid tablet disintegration.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Co-Processed Excipients
Excipient Details : HiCel CE15 offers a superior mouthfeel with less chalkiness and gritness in chewable tablets and orally disintegrating tablets (ODTs).
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Guar Gum Excipient
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Brand Name : HiCel MCC Spheres
Application : Co-Processed Excipients
Excipient Details : HiCel MCC Spheres are extremely versatile which are used for controlled release or sustained release formulations.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Co-Processed Excipients
Excipient Details : HiCel MCG is use in oral suspensions as a stabilizer. It is a good binder for tablets & excellent thickener as well.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Carboxymethyl cellulose sodium
Dosage Form : Tablet
Grade : Oral
Application : Co-Processed Excipients
Excipient Details : HiCel SMCC has unique combination which result in optimum compaction & superior flow properties.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Granulation
Excipient Details : HiCellac is used in direct compression & dry granulation suitable for low dose formulations where API content uniformity is critical.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Oral
Application : Granulation
Excipient Details : Hilose is used in oral pharmaceutical formulations as a super disintegrant for capsules and tablets formulations.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Croscarmellose Sodium
Dosage Form : Tablet
Grade : Oral
Brand Name : Croscarmellose Sodium
Application : Disintegrants & Superdisintegrants
Excipient Details : Croscarmellose sodium is used as a superdisintegrant in various oral solid dosage forms, such as tablets and ODTs.
Pharmacopoeia Ref : USP/BP/EP/PH.EUR
Technical Specs : Not Available
Ingredient(s) : Croscarmellose Sodium
Dosage Form : Tablet
Grade : Oral
Brand Name : Magnesium Stearate
Application : Lubricants & Glidants
Excipient Details : Magnesium stearate is the magnesium salt of stearic acid. It acts as a lubricating agent in tablet manufacturing.
Pharmacopoeia Ref : USP/BP/EP/PH.EUR
Technical Specs : Not Available
Ingredient(s) : Magnesium Stearate
Dosage Form : Tablet
Grade : Oral
Brand Name : Microcrystalline Cellulos...
Application : Fillers, Diluents & Binders
Excipient Details : Microcrystalline Cellulose is used as a diluent in oral dosage forms such as tablets.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Capsule
Grade : Oral
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
79
PharmaCompass offers a list of Apremilast API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Apremilast manufacturer or Apremilast supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Apremilast manufacturer or Apremilast supplier.
PharmaCompass also assists you with knowing the Apremilast API Price utilized in the formulation of products. Apremilast API Price is not always fixed or binding as the Apremilast Price is obtained through a variety of data sources. The Apremilast Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Apremilast manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Apremilast, including repackagers and relabelers. The FDA regulates Apremilast manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Apremilast API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Apremilast manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Apremilast supplier is an individual or a company that provides Apremilast active pharmaceutical ingredient (API) or Apremilast finished formulations upon request. The Apremilast suppliers may include Apremilast API manufacturers, exporters, distributors and traders.
click here to find a list of Apremilast suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Apremilast DMF (Drug Master File) is a document detailing the whole manufacturing process of Apremilast active pharmaceutical ingredient (API) in detail. Different forms of Apremilast DMFs exist exist since differing nations have different regulations, such as Apremilast USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Apremilast DMF submitted to regulatory agencies in the US is known as a USDMF. Apremilast USDMF includes data on Apremilast's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Apremilast USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Apremilast suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Apremilast Drug Master File in Japan (Apremilast JDMF) empowers Apremilast API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Apremilast JDMF during the approval evaluation for pharmaceutical products. At the time of Apremilast JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Apremilast suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Apremilast Drug Master File in Korea (Apremilast KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Apremilast. The MFDS reviews the Apremilast KDMF as part of the drug registration process and uses the information provided in the Apremilast KDMF to evaluate the safety and efficacy of the drug.
After submitting a Apremilast KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Apremilast API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Apremilast suppliers with KDMF on PharmaCompass.
A Apremilast written confirmation (Apremilast WC) is an official document issued by a regulatory agency to a Apremilast manufacturer, verifying that the manufacturing facility of a Apremilast active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Apremilast APIs or Apremilast finished pharmaceutical products to another nation, regulatory agencies frequently require a Apremilast WC (written confirmation) as part of the regulatory process.
click here to find a list of Apremilast suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Apremilast as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Apremilast API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Apremilast as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Apremilast and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Apremilast NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Apremilast suppliers with NDC on PharmaCompass.
Apremilast Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Apremilast GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Apremilast GMP manufacturer or Apremilast GMP API supplier for your needs.
A Apremilast CoA (Certificate of Analysis) is a formal document that attests to Apremilast's compliance with Apremilast specifications and serves as a tool for batch-level quality control.
Apremilast CoA mostly includes findings from lab analyses of a specific batch. For each Apremilast CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Apremilast may be tested according to a variety of international standards, such as European Pharmacopoeia (Apremilast EP), Apremilast JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Apremilast USP).